FDA Adverse Event Malfunction Summary report: N

TOTAL ASR FEM IMP SIZE 53

MDR report key: 1914965 · Received November 17, 2010

Report

Report Number
1818910-2010-07907
Event Type
Malfunction
Date Received
November 17, 2010
Report Date
February 11, 2014
Manufacturer
DEPUY INTL., LTD. - 8010379
Product Code
KWA
PMA / PMN Number
NA
Removal / Correction Number
Z-1749/1816-2011
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
EI
Reporter Occupation
UNKNOWN

Narratives

Additional Manufacturer Narrative · 1

ALTHOUGH, THE SPECIFIC NATURE OF THE PT'S COMPLAINT IS UNK, BECAUSE REVISION HAS BEEN RECOMMENDED BY DEPUY'S THIRD-PARTY CLAIMS ADMINISTRATOR, IT IS REASONABLE TO CONCLUDE THAT THE PT'S COMPLAINT HAS BEEN DETERMINED TO BE PRODUCT-RELATED. THIS COMPLAINT IS STILL UNDER INVESTIGATION. DEPUY WILL NOTIFY THE FDA OF THE RESULTS OF THIS INVESTIGATION ONCE IT HAS BEEN COMPLETED.

Additional Manufacturer Narrative · 1

THE ASR PLATFORM WAS VOLUNTARILY RECALLED FROM THE MARKET IN AUGUST 2010, AND THE ASR PRODUCT CODES ARE NOW CONSIDERED INACTIVE. FURTHER INVESTIGATION OF THIS INDIVIDUAL INCIDENT WILL NOT BE UNDERTAKEN, AS THERE IS AN ONGOING INVESTIGATION REGARDING THE ROOT CAUSE(S) AND/OR CORRECTIVE ACTIONS. REF. WWCAPA (B)(4).

Additional Manufacturer Narrative · 1

IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL MEDWATCH, A FOLLOW-UP MEDWATCH WILL BE FILED AS APPROPRIATE. DEPUY STILL CONSIDERS THIS CASE CLOSED TO CAPA.

Description of Event or Problem · 1

ASR REVISION RECOMMENDED.

Description of Event or Problem · 1

NEW ETQ RECORD CREATED IN ORDER TO UPDATE ETQ (LEGACY SYSTEM) COMPLAINT NUMBER (B)(4). REASON FOR ORIGINAL COMPLAINT - ASR REVISION, LEFT ASR HIP RESURFACING SYSTEM, REASON FOR REVISION: PAIN. UPDATE FROM (B)(6) SPREADSHEET 8TH NOV 2011: REASON FOR REVISION, LOT NO, DESC. UPDATE REC'D 11 FEB 2014 - ADDED FORM 57.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 TOTAL ASR FEM IMP SIZE 53 HIP KWA DEPUY INTL., LTD. - 8010379 NA 2643398

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention